{
  "id": 3709165,
  "title": "Citizens reiterates Mirum Pharmaceuticals stock rating on trial data",
  "url": "https://urgent.news/2026/08/27/citizens-reiterates-mirum-pharmaceuticals-stock-rating-on-trial-data",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-27T09:18:54.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/analyst-ratings/citizens-reiterates-mirum-pharmaceuticals-stock-rating-on-trial-data-93CH-4878682"
  },
  "original_language": "en",
  "account": "Citizens maintained an Outperform rating and $137.00 price target for Mirum Pharmaceuticals (NASDAQ:MIRM), indicating a 39% upside potential from the current $98.51 price. Analyst consensus favors a strong buy rating, with price targets spanning $118 to $183. Interim AZURE-1 data reinforced the firm's belief that brelovitug is a unique option within the HDV sector, significantly reducing risks for AZURE-1 and AZURE-4 outcomes. Week 24 response data showcased competitive efficacy for both approved and late-stage treatments at extended intervals, with a clean safety profile. Citizens anticipates continued effectiveness enhancements as brelovitug data and other HDV candidates accumulate. Though the 24-week data is likely sufficient for approval, real-world efficacy could surpass expectations. Brelovitug carries a 75% success probability, with peak sales potential reaching about $675 million, potentially lower than the company's optimistic $750 million estimate. Mirum shares surged in December following the licensing of brelovitug and surged another 20% after interim data release in April. The stock has yielded a 32% return over the past year, but InvestingPro analysis suggests potential overvaluation at present levels relative to its Fair Value estimate. A 30% pullback has occurred since July's market peak. The firm expects AZURE-1 data to reverse this downtrend and drive share prices upward. Mirum Pharmaceuticals revealed second-quarter net product sales of $176 million, up 37.5% year-over-year, despite a post-market decline triggered by a delayed volixibat filing and potential additional FDA discussions. The company has also upgraded its 2026 sales outlook, displaying confidence in future growth. H.C. Wainwright reinforced its Buy rating on Mirum Pharmaceuticals, preserving a $140.00 price target. These events underscore ongoing investor and analyst engagement in Mirum Pharmaceuticals.",
  "summary": null,
  "key_points": [
    "Citizens maintains Outperform rating and $137 price target for Mirum Pharmaceuticals",
    "Interim AZURE-1 data supports brelovitug as unique HDV sector option",
    "Mirum shares surged 20% after April interim data release"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "Citizens reiterates Market Perform on Inhibrx Biosciences stock",
        "url": "https://urgent.news/2026/08/27/citizens-reiterates-market-perform-on-inhibrx-biosciences-stock",
        "published": "2026-08-27T09:18:48.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}